Zydus Cadila has claimed eligibility for 180-day exclusivity periods linked to two generics that have just been approved by the US Food and Drug Administration.
Having received a nod from the US agency for its rivals to Imbruvica (ibrutinib) capsules in both 70mg and 140mg strengths, Zydus said that its generic version of the kinase inhibitor used to treat various cancers represented the first substantially complete